SUPPLEMENTARY MATERIAL

Table 1. Demographic information for healthy controls recruited for the study. Data are shownas mean ± standard deviation.

	Healthy
Table 1. Demographics	Controls
Total	12
Mean Age, years	24 ±7
Gender (M:F)	7:5

Table 2. Demographic and Disease Characteristics of Those Who Flared and Did Not FlareFollowing Discontinuation of Anti-TNF Therapy.

	8 Month Phase		——— End of Follow-Up———	
	No. (%) who	No. (%) who did	No. (%) who	No. (%) who did
	flared	not flare	flared	not flare
	Mean (Median)	Mean (Median)	Mean (Median)	Mean (Median)
	time to flare ¹	follow-up time	time to flare ¹	follow-up time
		among those		among those
		without flare ¹		without flare ¹
All patients in whom anti-TNF	39 (37)	67 (63)	65 (61)	41 (39)
was stopped (n = 106 unless	103 (105)	249 (250)	328 (172)	706 (673)
otherwise shown (%))				
Gender				
Females	29 (39)	46 (61)	50 (67)	25 (33)
remates	98 (105)	254 (250)	349 (179)	654 (643)
Males	10 (32)	21 (68)	15 (48)	16 (52)
Wrates	118 (126)	238 (251)	256 (149)	786 (834)
JIA Diagnosis				
Entended elice	8 (47)	9 (53)	12 (71)	5 (29)
Extended oligo	114 (105)	242 (244)	278 (162)	901 (1154)
	1 (11)	8 (89)	4 (44)	5 (56)
RF positive poly	39 (39)	264 (256)	660 (722)	686 (729)
	30 (37)	50 (63)	49 (61)	31 (39)
RF negative poly	102 (106)	248 (250)	313 (162)	678 (643)

ANA $(n = 103)^2$				
	22 (42)	31 (58)	34 (64)	19 (36)
Positive	127 (110)	249 (252)	335 (198)	712 (729)
Nagativa	15 (30)	35 (70)	28 (56)	22 (44)
Negative	63 (33)	249 (249)	318 (161)	701 (671)
RF $(n = 104)^3$				
Desitive	2 (22)	7 (78)	5 (56)	4 (44)
Positive	132 (132)	257 (252)	573 (687)	691 (759)
Negoting	36 (38)	59 (62)	59 (62)	36 (38)
Negative	98 (105)	248 (250)	309 (157)	689 (670)
Concurrent Methotrexate				
Vec	13 (32)	28 (68)	24 (59)	17 (41)
Yes	88 (105)	244 (250)	390 (176)	291 (172)
N-	26 (40)	39 (60)	41 (63)	24 (37)
No	111 (110)	252 (252)	686 (729)	720 (672)
Anti-TNF treatment				
Etonomont	32 (37)	55 (63)	51 (59)	36 (41)
Etanercept	102 (99)	252 (250)	297 (172)	740 (759)
Adalimumab	4 (29)	10 (71)	10 (71)	4 (29)
Adamnumad	91 (105)	250 (252)	559 (518)	468 (273)
	3 (60)	2 (40)	4 (80)	1 (20)
Infliximab	131 (131)	171 (171)	146 (137)	440 (440)
4 11				
age at enrollment (yrs) ⁴	17 (39)	27 (61)	28 (64)	16 (36)
< 10	111 (105	240 (245)	320 (201)	668 (591)
	22 (35)	40 (65)	37 (60)	25 (40)
≥ 10	97 (110)	255 (252)	334 (162)	730 (729)

Age at onset (yrs) $(n = 105)^5$				
< 5.0	25 (46)	29 (54)	35 (65)	19 (35)
	110 (105)	240 (244)	274 (133)	621 (510)
≥ 5.0	14 (27)	37 (73)	29 (57)	22 (43)
	91 (92)	256 (252)	364 (192)	779 (807)
Age at diagnosis (yrs)				
. 5.0	24 (48)	26 (52)	31 (62)	19 (38)
< 5.0	109 (105)	239 (245)	218 (112)	621 (510)
≥ 5.0	15 (27)	41 (73)	34 (61)	22 (39)
	94 (114)	255 (252)	428 (277)	779 (807)
Disease duration at enrollment				
$(mos)(n = 105)^5$				
< 6	0	0	0	0
	0	0	0	0
(1)	0	2 (100)	1 (50)	1 (50)
6 – 12	0	206 (206)	949 (949)	131 (131)
× 12	39 (38)	64 (61)	63 (61)	40 (39)
> 12	103 (105)	532 (250)	305 (162)	720 (701)

Age, first occurrence of CID (yrs)($n = 105$) ⁵				
< 5.0	11 (52) 147 (120)	10 (48) 223 (245)	14 (67) 220 (211)	7 (33) 421 (224)
≥ 5.0	28 (33)	56 (67)	50 (60)	34 (40)
	86 (99)	253 (252)	341 (160)	764 (792)
Time from disease onset to first CID (mos)(n=105) ⁵				

< 6	0	0	0	0
	0	0	0	0
6 – 12	3 (19)	13 (81)	8 (50)	8 (50)
	129 (106)	248 (252)	530 (337)	768 (959)
10	36 (40)	53 (60)	56 (63)	33 (37)
> 12	101 (105)	249 (250)	284 (153)	691 (671)
< 6	15 (28)	39 (72)	32 (59)	22 (41)
< 6	95 (105)	256 (252)	405 (277)	636 (656)
6 - 12	9 (50)	9 (50)	12 (67)	6 (33)
> 12	128 (114)	239 (238) 19 (56)	289 (182) 21 (62)	804 (888) 13 (38)
	96 (105)	240 (245)	233 (143)	779 (805)


Time in days

2 Three ANA results unknown

3 Two RF results unknown (in order to be included in the analysis the two patients with unknown RF results were considered to be RF (-).


4 Cut-points for continuous numeric variables were chosen based upon clinical relevance and distribution of values in the dataset.


5 One value unknown





Representative ELISA results with serial dilution of 10 sera samples from patients with JIA, 3 non-JIA patients with other rheumatic diseases, and control sera or plasma from 12 healthy individuals. Samples were serially diluted as indicated and tested for DEK antibody levels. Results shown are the optical density (O.D.) obtained in this individual ELISA minus the background.





Supplemental Figure 2. DEK antibody levels at the time of stopping anti-TNF therapy do not predict the probability of subsequent disease flare. 92 out of 106 patient samples were available and analyzed for DEK antibody levels. Sera collected at time 0 (after six months of successful anti-TNF treatment) were analyzed for DEK antibody levels. DEK antibody levels with a mean and SD of 0.0917 ± 0.38 were detected in the 30 patients that flared within 14 months as compared to DEK antibody levels and SD of 0.0365 ± 0.3 in 62 patients with clinically inactive disease (CID) for at least 14 months (Student T-test, P=0.49).